NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Progyny, Inc. (NASDAQ: PGNY) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.If you are a long-term PGNY stockholder please contact Justin Kuehn, Esq. here, by email at [email protected], or call (833) 672-0814. The consultation and case ...

Paul Franke's Background and Investment Approach - Paul Franke is a private investor and speculator with 38 years of trading experience, known for his contrarian stock selection style and algorithm-based analysis of fundamental and technical data [1] - He developed the "Victory Formation" system, which identifies supply/demand imbalances through specific stock price and volume movements, and suggests using 10% or 20% stop-loss levels on individual choices [1] - Franke recommends a diversified approach of owning at least 50 well-positioned stocks to achieve regular stock market outperformance [1] - His "Bottom Fishing Club" articles focus on deep-value candidates or stocks experiencing a major reversal in technical momentum to the upside, while "Volume Breakout Report" articles discuss positive trend changes backed by strong price and volume trading action [1] Paul Franke's Achievements and Rankings - Franke was consistently ranked among top investment advisors nationally for stock market and commodity macro views by Timer Digest during the 1990s [1] - He was ranked 1 in the Motley Fool CAPS stock picking contest during parts of 2008 and 2009, out of 60,000+ portfolios [1] - As of September 2024, Franke was ranked in the Top 3% of bloggers by TipRanks for 12-month stock picking performance on suggestions made over the last decade [1] Paul Franke's Professional Experience - Franke was Editor and Publisher of the Maverick Investor newsletter during the 1990s, widely quoted by CNBC, Barron's, the Washington Post, and Investor's Business Daily [1] - He served as Director of Research at Quantemonics Investing from 2010-13, running several model portfolios on the Covestor.com mirror platform, including the least volatile, lowest beta, fully-invested equity portfolio on the site [1]

SAN DIEGO, Dec. 18, 2024 /PRNewswire/ -- Shareholder rights law firm Robbins LLP is investigating Progyny, Inc. (NASDAQ: PGNY) to determine whether certain Progyny officers and directors violated securities laws and breached fiduciary duties to shareholders. Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States.What Now: If you own shares of Progyny, Inc. and have lost money in your investment, contact us for more inf ...

SAN DIEGO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Progyny, Inc. (NASDAQ: PGNY) to determine whether certain Progyny officers and directors violated securities laws and breached fiduciary duties to shareholders. Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. What Now: If you own shares of Progyny, Inc. and have lost money in your investment, contact us for mor ...

I recommended a buy rating for Progyny, Inc. (NASDAQ: PGNY ) when I wrote about it on 3rd June this year, as I saw no change to the long-term growth outlook and that anyI consider an investment ideal if it performs its core business in a sector projected to experience structural (organic) growth in excess of GDP growth over the next 5-10 years; profits from sustainable competitive advantages that translate into attractive unit economics; In the hands of competent, ethical, and long-term thinkers; with a fai ...

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or ...

NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women’s health benefits solution, today announced that Pete Anevski, Progyny’s Chief Executive Officer, and Mark Livingston, Chief Financial Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 8:00 a.m. GMT (3:00 a.m. EST). A live audiocast and replay will be available from the Events and Presentations section of P ...

Shares of leading fertility benefits manager Progyny (PGNY -19.09%) were down 19% as of 4 p.m. ET on Wednesday, according to data provided by S&P Global Market Intelligence.The upstart healthcare company reported its results for the third quarter yesterday, missing analysts' expectations on the top line, delivering only 2% growth during the third quarter. Making matters worse, Progyny didn't assuage the market's fears by guiding for Q4 sales growth of only 1.5% at the midpoint, prompting many Wall Street ex ...

Progyny, Inc (NASDAQ:PGNY) Q3 2024 Earnings Conference Call November 12, 2024 4:45 PM ET Company Participants James Hart - Investor Relations Peter Anevski - CEO Michael Sturmer - President Mark Livingston - CFO Conference Call Participants Anne Samuel - JPMorgan Allen Lutz - Bank of America Sarah James - Cantor Fitzgerald Michael Cherny - Leering Partners Glen Santangelo - Jefferies Jailendra Singh - Truist Securities Stephanie Davis - Barclays Scott Schoenhaus - KeyBanc Richard Close - Canaccord Genuity ...

Progyny (PGNY) came out with quarterly earnings of $0.40 per share, beating the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $0.16 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 8.11%. A quarter ago, it was expected that this provider of fertility and family building benefits would post earnings of $0.36 per share when it actually produced earnings of $0.43, delivering a surprise of 19.44%.Over th ...